According to a new report published by Introspective Market Research, titled, Personalized Genomics Market by Test Type, Application, and End User, The Global Personalized Genomics Market Size Was Valued at USD 5.34 Billion in 2023 and is Projected to Reach USD 12.48 Billion by 2032, Growing at a CAGR of 9.90%. The global personalized genomics market is witnessing steady growth, driven by technological innovations in sequencing and the rising need for tailored healthcare solutions. Personalized genomics focuses on analyzing an individual’s genetic code to provide unique insights into disease predisposition, treatment responses, and lifestyle optimization. Unlike traditional medical practices, this approach emphasizes prevention and personalization, leading to improved patient outcomes.
The demand for genetic testing services is expanding rapidly across clinical diagnostics, pharmacogenomics, and direct-to-consumer applications. Falling sequencing costs, combined with advancements in bioinformatics and AI-based interpretation, are making personalized genomic services more accessible to patients, physicians, and consumers worldwide. As awareness of preventive health grows, the adoption of personalized genomics is expected to expand significantly across developed and emerging regions.
The Personalized Genomics Market is segmented into Test Type, Application, and End User.
-
By Test Type, the market is categorized into Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing, and Others.
-
By Application, the market is categorized into Oncology, Rare Diseases, Pharmacogenomics, Ancestry & Lifestyle, and Others.
-
By End User, the market is categorized into Hospitals & Clinics, Research Organizations, and Direct-to-Consumer.
A major growth driver for the personalized genomics market is the increasing adoption of genetic testing for preventive healthcare. With growing awareness of chronic diseases and hereditary risks, patients and healthcare providers are leveraging genetic insights to design proactive treatment and lifestyle strategies. The growing number of government initiatives, research collaborations, and private investments in genomics further accelerate adoption rates worldwide.
A significant opportunity lies in the expansion of direct-to-consumer (DTC) genomics services. As consumers become more health-conscious, they are increasingly interested in genetic testing for ancestry, nutrition, and wellness applications. Companies offering user-friendly genetic kits and AI-based data analysis platforms are expected to capture strong market potential, particularly in Asia-Pacific and other emerging economies with growing healthcare digitization.
Detailed Segmentation
Personalized Genomics Market, Segmentation
The Personalized Genomics Market is segmented on the basis of Test Type, Application, and End User.
Test Type
The Test Type segment is further classified into Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing, and Others. Among these, the Whole Genome Sequencing sub-segment accounted for the highest market share in 2023. Its dominance stems from its ability to deliver comprehensive genetic insights, widely used in disease prediction, pharmacogenomics, and personalized wellness programs. Ongoing improvements in sequencing accuracy and affordability are expected to boost this sub-segment’s adoption.
Application
The Application segment is further classified into Oncology, Rare Diseases, Pharmacogenomics, Ancestry & Lifestyle, and Others. Among these, the Oncology sub-segment accounted for the highest market share in 2023. Cancer treatment increasingly relies on genomic profiling to identify tumor mutations and enable precision therapies. Rising cancer prevalence, combined with research funding and healthcare system integration of genomics, is driving this segment’s strong growth trajectory.
Some of The Leading/Active Market Players Are-
- Illumina, Inc. (USA)
- Thermo Fisher Scientific Inc. (USA)
- F. Hoffmann-La Roche AG (Switzerland)
- BGI Genomics Co., Ltd. (China)
- 23andMe, Inc. (USA)
- Myriad Genetics, Inc. (USA)
- Gene by Gene, Ltd. (USA)
- Color Health, Inc. (USA)
- Dante Labs (Italy)
- QIAGEN N.V. (Netherlands/Germany)
- Nebula Genomics (USA)
- Veritas Genetics (USA)
- Mapmygenome India Ltd. (India)
- Oxford Nanopore Technologies plc (UK)
- Invitae Corporation (USA)
- other active players.
Key Industry Developments
- In March 2024, Illumina introduced its next-generation sequencing platform with improved accuracy and faster turnaround times.
The innovation is designed to reduce the cost of genome sequencing and accelerate the adoption of personalized genomics in clinical settings. - In August 2024, 23andMe announced a strategic partnership to integrate consumer genomics with digital health applications.
The partnership aims to provide personalized health insights that combine genetic, lifestyle, and behavioral data for enhanced wellness management.
Key Findings of the Study
- Whole Genome Sequencing dominated the test type segment in 2023.
- Oncology was the leading application segment.
- North America accounted for the largest market share.
- Preventive healthcare adoption is a key growth driver.
- Direct-to-consumer genomics offers significant opportunities.
